PMID- 34976180
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220104
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 13
IP  - 1
DP  - 2022
TI  - Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after 
      neoadjuvant chemoradiotherapy: a potential prognostic marker.
PG  - 162-173
LID - 10.7150/jca.64082 [doi]
AB  - Background: Neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal 
      cancer (LARC) has been shown to improve sphincter preservation and local pelvic 
      control, but the efficacy of nCRT plateaus due to metastasis. CXC chemokine 
      ligand 12 (CXCL12) has a critical impact on cancer development and metastasis. 
      Methods: By investigating public databases containing LARC patient data, CXCL12, 
      CXCR4 and FAPalpha expression was analyzed via the Tumor Immune Estimation Resource 
      (TIMER) and GSEA. Immunohistochemistry was applied to a total of 121 surgically 
      resected specimens consisting of 61 LARCs after nCRT and 60 LARCs with no nCRT 
      and 16 cases with endoscopic resection of high-grade colorectal adenoma. Results: 
      By investigating public databases containing LARC patient data, CXCL12 expression 
      is correlated with poor prognosis, immune cell infiltration, epithelial- 
      mesenchymal transition, and angiogenesis in LARC. Furthermore, radiation 
      selectively induced CXCL12, CXCR4 and FAPalpha expression in tumor tissues. 
      Immunohistochemistry results showed that the levels of CXCL12, CXCR4, and FAPalpha in 
      LARC cells after nCRT were higher than in LARC cells untreated with nCRT (p < 
      0.001 for each). Elevated levels of CXCL12 in the plasma membrane of LARC cells 
      after nCRT demonstrated an association with the period of freedom from recurrence 
      (FFR) in univariate and multivariate survival analyses (p = 0.005 and p = 0.031, 
      respectively). Conclusions: The expression of CXCL12 may influence the survival 
      and invasive properties of LARC cells during nCRT and promote cancer recurrence. 
      We suggest that CXCL12 expression in the plasma membrane of radioresistant LARC 
      cells may be a predictive factor of recurrence and a viable therapeutic strategy 
      to control radioresistant LARC recurrence.
CI  - (c) The author(s).
FAU - Kim, Sup
AU  - Kim S
AD  - Department of Radiation Oncology, Chungnam National University School of 
      Medicine, 288 Munhwa Street, Daejeon 35015, Korea.
AD  - Department of Radiation Oncology, Chungnam National University Hospital, 282 
      Munwha-ro, Daejeon 35015, Korea.
FAU - Yeo, Min-Kyung
AU  - Yeo MK
AD  - Department of Pathology, Chungnam National University School of Medicine, 266 
      Munhwa Street, Daejeon 35015, Korea.
AD  - Department of Pathology, Chungnam National University Hospital, 282 Munwha-ro, 
      Daejeon 35015, Korea.
FAU - Kim, Jun-Sang
AU  - Kim JS
AD  - Department of Radiation Oncology, Chungnam National University School of 
      Medicine, 288 Munhwa Street, Daejeon 35015, Korea.
AD  - Department of Radiation Oncology, Chungnam National University Hospital, 282 
      Munwha-ro, Daejeon 35015, Korea.
FAU - Kim, Ji-Yeon
AU  - Kim JY
AD  - Department of Surgery, Division of Colorectal Surgery, Chungnam National 
      University School of Medicine, Daejeon, Republic of Korea.
FAU - Kim, Kyung-Hee
AU  - Kim KH
AD  - Department of Pathology, Chungnam National University School of Medicine, 266 
      Munhwa Street, Daejeon 35015, Korea.
AD  - Department of Pathology, Chungnam National University Sejong Hospital, 20 Bodeum 
      7-ro, Sejong-si 30099, Korea.
LA  - eng
PT  - Journal Article
DEP - 20220101
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC8692683
OTO - NOTNLM
OT  - CXCL12
OT  - locally advanced rectal adenocarcinoma
OT  - neoadjuvant chemoradiotherapy
OT  - plasma membrane
OT  - recurrence
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2022/01/04 06:00
MHDA- 2022/01/04 06:01
PMCR- 2022/01/01
CRDT- 2022/01/03 05:40
PHST- 2021/06/20 00:00 [received]
PHST- 2021/11/10 00:00 [accepted]
PHST- 2022/01/03 05:40 [entrez]
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/01/04 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - jcav13p0162 [pii]
AID - 10.7150/jca.64082 [doi]
PST - epublish
SO  - J Cancer. 2022 Jan 1;13(1):162-173. doi: 10.7150/jca.64082. eCollection 2022.